Lupin's US Generics Turn Corner, Upcoming Launches To Fuel Momentum
A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.
You may also be interested in...
Indian drug makers are looking in much better shape as US pricing pressures ease and the domestic market regains its double-digit growth, analysts say.
In line with its strategy to transition to more complex generics, Lupin has announced the exclusive launch of its generic version of Gilead Science’s Ranexa 500mg and 1,000mg extended-release tablets in the US.
Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit
Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.